Entyvio vs Stelara for Ulcerative Colitis: Which to Choose?

Entyvio and Stelara are two of the most common biologics used for ulcerative colitis after a patient has failed an anti-TNF, and they are increasingly considered first-line options as well. Both avoid the systemic TNF blockade that raises infection risk in anti-TNF therapy, but they do so through very different mechanisms. Entyvio is gut-selective. Stelara blocks an upstream cytokine pathway that affects inflammation throughout the body. For UC patients weighing a second-line biologic or looking for a safer first-line option, the decision often hinges on onset of action, efficacy in anti-TNF experienced patients, and dosing convenience. This guide walks through the evidence UC patients need to make an informed entyvio vs stelara ulcerative colitis decision.

Gut-Selective vs IL-12/23 Mechanism

Entyvio (vedolizumab) binds the alpha-4-beta-7 integrin, a receptor found almost exclusively on gut-homing lymphocytes. By blocking these immune cells from entering inflamed colonic tissue, it quiets UC inflammation without meaningfully suppressing the immune system elsewhere. Stelara (ustekinumab) binds the p40 subunit shared by interleukin-12 and interleukin-23, dampening T-cell subsets that drive inflammation both in the gut and in extraintestinal tissues. The vedolizumab vs ustekinumab UC distinction shapes everything downstream. Entyvio has the narrowest immune footprint of any UC biologic. Stelara has a broader mechanism that extends to extraintestinal manifestations but still avoids the systemic TNF blockade linked to higher anti-TNF infection rates.

Efficacy in UC

No head-to-head randomized trial has compared vedolizumab and ustekinumab in UC, so the comparison rests on network meta-analyses and real-world cohorts. Stelara's UNIFI trial established efficacy in both biologic-naive and biologic-experienced UC patients. Vedolizumab's GEMINI-1 trial showed strong maintenance remission rates in UC, and the VARSITY head-to-head trial demonstrated vedolizumab's superiority over adalimumab at 52 weeks. A 2023 network meta-analysis of UC biologics ranked both drugs favorably, with differences that were small and statistically uncertain. Real-world cohorts have generally shown similar 12-month clinical remission rates, with some evidence that Entyvio produces higher rates of endoscopic remission in biologic-naive patients and Stelara has an edge in anti-TNF experienced patients.

Onset of Action

Stelara tends to produce symptom improvement earlier than Entyvio in UC. Most Stelara patients see meaningful response within the first two months after IV induction. Entyvio's onset is slower, with many patients not reaching full response until week 10 to 14 and some continuing to improve through week 26. For UC patients with active, symptomatic disease who cannot tolerate a long ramp-up, the entyvio vs stelara UC side effects and efficacy comparison in the early weeks often tips toward Stelara. For patients in a less acute state or those who have already failed an anti-TNF and are not in a flare, Entyvio's slower onset is typically manageable with supportive care.

Safety and Infection Risk

Both drugs have favorable safety profiles, but the risk signals differ slightly. Entyvio's gut-selective action produces very low rates of systemic infection, and its long-term safety profile is among the cleanest of any IBD biologic for non-GI infections. Stelara also has a strong safety record with a lower infection signal than anti-TNFs, though not quite as narrow as Entyvio. A 2024 Swedish registry study flagged a higher rate of serious gastrointestinal infections on vedolizumab compared with anti-TNFs, while overall systemic infection rates were lower. Stelara carries a boxed warning for serious infections and rare malignancies. Neither drug typically requires combination therapy with an immunomodulator, which simplifies long-term management for UC patients.

Dosing and Administration

Entyvio starts with three 300 mg IV infusions at weeks 0, 2, and 6, followed by maintenance every 8 weeks. After IV induction, patients who respond by week 6 can switch to a 108 mg subcutaneous pen every 2 weeks, according to Takeda's dosing information. Stelara uses a single weight-based IV induction dose at week 0, then transitions to a 90 mg subcutaneous injection every 8 weeks that patients give themselves at home, per Janssen's Stelara dosing information. For UC patients who want to minimize infusion center visits, Stelara converts to home-based SC injection sooner (after one IV dose) compared with Entyvio's three IV induction doses before SC conversion. For patients who prefer less frequent dosing over the long term, both drugs share an every-8-week cadence.

Extraintestinal Manifestations

UC patients with joint pain, psoriasis, or uveitis often respond better to Stelara than to Entyvio. Ustekinumab has approved indications in plaque psoriasis and psoriatic arthritis, and its IL-12/23 blockade addresses inflammation across multiple tissues. Entyvio's gut-selective action means it does not treat extraintestinal disease well. A UC patient with concurrent moderate plaque psoriasis, for example, typically gets more clinical benefit from a single ustekinumab prescription than from Entyvio plus a separate dermatology-prescribed agent. Patients without extraintestinal involvement who are prioritizing the narrowest possible immune suppression may lean toward Entyvio.

Choosing With Your GI

There is no single correct answer in the UC second-line biologic decision between Entyvio and Stelara. Stelara tends to win on speed of onset, efficacy in anti-TNF experienced patients, and coverage of extraintestinal manifestations. Entyvio tends to win on systemic infection risk and the narrowest immune footprint. Your gastroenterologist will weigh disease severity, prior biologic exposure, comorbidities, and insurance coverage when making the recommendation. Before starting either drug, ask your GI how response will be measured and at what week, what side effects warrant a call between visits, and whether therapeutic drug monitoring will be part of your follow-up. A simple log of stool frequency, urgency, blood, and any new joint or skin symptoms between GI visits gives your care team the data to recognize early loss of response before a full flare returns.